The global prostate health market is anticipated to grow at a considerable CAGR of 8.8% during the forecast period (2021-2027). The major factor attributing to the growth of the market is the high prevalence rate of prostate cancer. The increasing demand for prostate cancer drugs has driven the overall market. As a rsut of which market key players are inclined towards launching new drugs to cater increasing demand for advanced therapeutics for specific and effective treatment. For instance, in June 2021, Novartis announced that the FDA has granted Breakthrough Therapy designation (BTD) to 177Lu-PSMA-617, an investigational radioligand therapy for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Breakthrough therapy designation was granted based on positive data from the pivotal, Phase III VISION study evaluating 177Lu-PSMA-617, a targeted radioligand therapy, plus standard of care (SOC), compared to SOC alone, in patients with progressive PSMA-positive mCRPC. The Phase III VISION study demonstrated that Lu-PSMA-617 significantly improved overall survival and radiographic progression-free survival for men with progressive PSMA-positive mCRPC.
Browse the full report description of "Global Prostate Health Market Size, Share & Trends Analysis Report by Disease Indication (Prostate Cancer, Benign Prostatic Hyperplasia, and Prostatitis), and by Treatment (Chemotherapy, Biological Therapy, Hormone Therapy, and Others), Forecast (2021-2027)" at https://www.omrglobal.com/industry-reports/prostate-health-market
Further, in December 2020, FDA approved Orgovyx (relugolix) for the treatment of adult patients with advanced prostate cancer. In a large clinical trial, the drug was shown to be more effective at reducing testosterone levels in men with advanced prostate cancer. Orgovyx is an orally administered treatment that works by blocking the pituitary gland from making hormones called luteinizing hormone and follicle-stimulating hormone, thereby diminishing the amount of testosterone the testicles can make. The most frequently reported side effects of Orgovyx included hot flush, increased glucose and triglycerides, musculoskeletal pain, decreased hemoglobin, fatigue, constipation, diarrhea, and increased liver enzyme levels.
In May 2020, Zydus Cadila announced that it is launching Enzalutamide, a highly effective drug for the treatment of Prostate Cancer, under the brand name 'Obnyx' in India. In a step that can considerably reduce treatment cost by almost 70%.
Market Coverage
• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered-
o By Disease Indication
o By Treatment
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape- including Abbott Laboratories, Amgen Inc., Astellas Pharma Inc., AstraZeneca, Bayer AG., BDR Pharmaceuticals International Pvt. Ltd., and others.
Key questions addressed by the report
• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?
Global Prostate Health Market Report Segment
By Disease Indication
• Prostate Cancer
• Benign Prostatic Hyperplasia
• Prostatitis
By Treatment
• Chemotherapy
• Biological Therapy
• Hormone Therapy
• Others
Global Prostate Health Market Report Segment by Region
North America
• United States
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East & Africa
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/prostate-health-market